Update shared on 22 Oct 2025
Fair value Increased 5.54%Analyst Commentary Highlights Ionis Pharmaceuticals’ Upward Price Target and Valuation Amid Key Clinical Wins
Ionis Pharmaceuticals’ analyst price target has been raised from approximately $73 to $77. Analysts cite stronger-than-expected clinical and commercial progress across key late-stage programs, as well as expanded opportunities in rare disease markets.
Analyst Commentary
Recent analyst updates reflect a dynamic outlook for Ionis Pharmaceuticals, highlighting notable achievements but also emphasizing several areas where potential challenges may impact further upside. These perspectives provide a nuanced view of the company’s current valuation and future growth trajectory.
Bullish Takeaways
- Bullish analysts are raising price targets in response to positive late-stage trial results for compounds like Tryngolza and olezarsen. They cite blockbuster potential in severe hypertriglyceridemia and acute pancreatitis indications.
- Recent regulatory approvals, including Dawnzera for hereditary angioedema and progress with CNS-focused drugs, have strengthened confidence in the company’s commercial execution and portfolio diversification.
- Expanded label opportunities and demonstrated efficacy in ultra-rare diseases, such as Alexander disease, are seen as supportive of long-term growth and increased market reach.
- Continued momentum across commercial and near-commercial programs, along with positive management commentary on pricing leverage, reinforce the view that Ionis is well-positioned for profitability and potential share outperformance.
Bearish Takeaways
- Bearish analysts caution that some of Ionis’ new indications, while scientifically impressive, represent smaller market opportunities and may offer only modest near-term earnings contributions.
- There are concerns regarding the revenue impact from recent partner Q2 performance, particularly related to AstraZeneca. This performance did not meet consensus estimates and is considered a negative for Ionis’ valuation outlook.
- Despite positive clinical data, a few analysts note that increased competition and the need for significant launch investments in ultra-rare conditions could temper margin expansion in the near term.
- Some coverage maintains a hold rating, reflecting caution over the competitive landscape, execution risks, and market uptake for new therapies as the company prepares for multiple key phase 3 readouts.
What's in the News
- Ionis Pharmaceuticals announced positive Phase 3 results for olezarsen in severe hypertriglyceridemia, reporting up to 72% triglyceride reduction and 85% reduction in acute pancreatitis events. A supplemental new drug application will be submitted to the FDA by year-end (Key Developments).
- The FDA approved DAWNZERA™ (donidalorsen), making it the first RNA-targeted medicine for hereditary angioedema. The therapy significantly reduced HAE attacks in clinical trials and is available via self-administered autoinjector (Key Developments).
- The pivotal trial for zilganersen in Alexander disease demonstrated statistically significant clinical benefit and a favorable safety profile. Ionis plans to submit a new drug application in early 2026 and may launch an Expanded Access Program in the US (Key Developments).
- The FDA granted Breakthrough Therapy designation to ION582 for the treatment of Angelman syndrome, expediting its review after promising Phase 1/2 data showed improvement across key functional domains (Key Developments).
- Arrowhead Pharmaceuticals filed a legal challenge asserting that Ionis's US Patent No. 9,593,333 is invalid and not infringed by Arrowhead's investigational plozasiran, which is under FDA review (Key Developments).
Valuation Changes
- Consensus Analyst Price Target: Increased from approximately $73 to $77. This reflects a modest upward revision based on an updated company outlook.
- Discount Rate: Risen marginally from 7.08% to 7.12%. This indicates a slight adjustment in perceived risk or cost of capital.
- Revenue Growth: Edged down slightly from 17.46% to 17.32%. This suggests analysts expect a marginally slower top-line expansion rate.
- Net Profit Margin: Improved modestly from 16.11% to 16.16%. This points to a slightly higher anticipated level of profitability.
- Future P/E: Increased from 59.3x to 62.7x. This indicates higher forward valuation expectations based on revised earnings forecasts.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.